Bone marrow-derived mesenchymal stem cell-derived exosome-loaded miR-129-5p targets high-mobility group box 1 attenuates neurological-impairment after diabetic cerebral hemorrhage

Figure 3 Bone marrow-derived mesenchymal stem cell-derived exosome attenuated neurological deficits in vivo. A: Dil-labeled bone marrow-derived mesenchymal stem cell-derived exosomes (BMSC-exo) were injected in the tail vein of mice; B: Microglia (green) were labeled with ionized calcium-binding adaptor molecule 1 to observe the phagocytosis of BMSC-exo (red) by microglia. Scale bar = 50 μm; C: Immunofluorescence staining to observe the location of immunoglobulin G expression. Scale bar = 100 μm; D: Brain slices and hematoma volume were analyzed based on T2 magnetic resonance imaging. Experimental data are expressed as mean ± SD. ^aP < 0.05, intracerebral hemorrhage (ICH) + diabetes mellitus (DM) group vs ICH + DM + BMSC-exo group, t-test; E: Brain water content analysis. Experimental data are expressed as mean ± SD. ^aP < 0.01, ICH + DM group vs ICH + DM + BMSC-exo group, t-test; F: Neurological function scores and balance beam scores. Experimental data are expressed as mean ± SD. ^aP < 0.05, ICH + DM group vs ICH + DM + BMSC-exo group, t-test; G: The blood glucose levels of mice in each group were detected, and it was found that BMSC-exo could not reduce the blood glucose levels after diabetic cerebral hemorrhage in mice. Con: Control; BMSC-exo: Bone marrow mesenchymal stem cell derived exosomes; ICH: Intracerebral hemorrhage; DM: Diabetes mellitus; IgG: Immunoglobulin G.